{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=30",
    "query": {
      "intervention": "Placebo Intravenous",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 2347,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T11:33:54.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00223704",
      "title": "Bradykinin Receptor Antagonism During Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cardiopulmonary Bypass",
        "Inflammation",
        "Fibrinolysis",
        "Surgery"
      ],
      "interventions": [
        {
          "name": "HOE 140",
          "type": "DRUG"
        },
        {
          "name": "Aminocaproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 150,
      "start_date": "2006-05",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223704"
    },
    {
      "nct_id": "NCT01367535",
      "title": "Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "SC Methylnaltrexone (MNTX)",
          "type": "DRUG"
        },
        {
          "name": "IV Methylnaltrexone (MNTX)",
          "type": "DRUG"
        },
        {
          "name": "Oral Paroxetine",
          "type": "DRUG"
        },
        {
          "name": "SC Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 54,
      "start_date": "2006-03",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01367535"
    },
    {
      "nct_id": "NCT03810417",
      "title": "Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Digoxin Antibodies Fab Fragments",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Baseline EO > 360 pM",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "EO < 360 pM",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2019-07-22",
      "completion_date": "2024-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03810417"
    },
    {
      "nct_id": "NCT00402350",
      "title": "Staccato Fentanyl Single and Multidose PK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breakthrough Pain"
      ],
      "interventions": [
        {
          "name": "Inhaled Placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Fentanyl 25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 2",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 4",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 6",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 51,
      "start_date": "2006-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402350"
    },
    {
      "nct_id": "NCT05747924",
      "title": "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "FSHD",
        "FSHD1",
        "FSHD2",
        "FMD",
        "FMD2",
        "Fascioscapulohumeral Muscular Dystrophy",
        "Fascioscapulohumeral Muscular Dystrophy Type 1",
        "Fascioscapulohumeral Muscular Dystrophy Type 2",
        "Dystrophies, Facioscapulohumeral Muscular",
        "Dystrophy, Facioscapulohumeral Muscular",
        "Facioscapulohumeral Muscular Dystrophy 1",
        "Facioscapulohumeral Muscular Dystrophy 2",
        "Facio-Scapulo-Humeral Dystrophy",
        "Atrophy, Facioscapulohumeral",
        "Atrophies, Facioscapulohumeral",
        "Facioscapulohumeral Atrophy",
        "Muscular Dystrophies",
        "Muscular Dystrophy, Facioscapulohumeral",
        "FSH Muscular Dystrophy",
        "Landouzy Dejerine Dystrophy",
        "Landouzy-Dejerine Muscular Dystrophy",
        "Dystrophies, Landouzy-Dejerine",
        "Dystrophy, Landouzy-Dejerine",
        "Landouzy-Dejerine Syndrome",
        "Muscular Dystrophy, Landouzy Dejerine",
        "Progressive Muscular Dystrophy",
        "FSH"
      ],
      "interventions": [
        {
          "name": "AOC 1020",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2023-04-04",
      "completion_date": "2026-03-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05747924"
    },
    {
      "nct_id": "NCT06021054",
      "title": "An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Veligrotug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viridian Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 188,
      "start_date": "2023-11-01",
      "completion_date": "2025-07-25",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06021054"
    },
    {
      "nct_id": "NCT05250856",
      "title": "CNP-201 in Subjects With Peanut Allergy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "CNP-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "COUR Pharmaceutical Development Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "16 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2022-03-14",
      "completion_date": "2023-12-12",
      "has_results": false,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Mission Viejo, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05250856"
    },
    {
      "nct_id": "NCT02611830",
      "title": "Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Vedolizumab 300 mg IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab 108 mg SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 383,
      "start_date": "2015-12-18",
      "completion_date": "2018-08-21",
      "has_results": true,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 28,
      "location_summary": "Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Middletown",
          "state": "Connecticut"
        },
        {
          "city": "Inverness",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611830"
    },
    {
      "nct_id": "NCT02589600",
      "title": "Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporotic Fractures",
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "calcium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Susan L. Greenspan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "65 Years and older · Female only"
      },
      "enrollment_count": 310,
      "start_date": "2016-01",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2023-09-26",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 1,
      "location_summary": "New Kensington, Pennsylvania",
      "locations": [
        {
          "city": "New Kensington",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02589600"
    },
    {
      "nct_id": "NCT03114657",
      "title": "A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Crenezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 806,
      "start_date": "2017-03-29",
      "completion_date": "2019-06-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-16",
      "last_synced_at": "2026-10-15T11:33:54.580Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03114657"
    }
  ]
}